Trial
NCT02480010
A Study of Pertuzumab in Participants With Prostate Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Prostate Cancer
Intervention
Pertuzumab
Why stopped
The study was terminated at the time of interim analysis since none of the participants showed a PSA response.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-09-18